Early access
Sign in
Enrolling by invitationNo phase

Following people with adrenal gland diseases over time

Studies tumor features, complications and outlook in adults with adrenal gland tumors.

Key facts

Who runs it
Seoul National University Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
A Prospective Cohort Study for Patients With Adrenal Diseases
Status
Enrolling by invitation
People taking part
1,500 people, planned
Started
1 Oct 2018
Expected to end
31 Dec 2027
Type of study
Observational, 5 groups
Treatments tested
  • Hormone study and Imaging study
Record updated
18 March 2020

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who were newly diagnosed with an adrenal gland disease. It follows them with hormone tests and imaging.

Age
19 years or older
Sex
All sexes
Disease stage
Newly diagnosed adrenal disease, such as adrenal incidentaloma (a lump found by chance), pheochromocytoma, primary aldosteronism, adrenal Cushing syndrome or adrenocortical carcinoma.
Earlier treatment
People who take steroids by mouth or into a vein cannot join.

Main reasons for not taking part

  • Earlier or current adrenal disease
  • Taking oral or intravenous steroids
  • History of major depressive disorder or chronic alcohol use
  • Any cancer that may have spread to the adrenal gland
  • Acute illness, such as acute coronary syndrome within 4 weeks or an illness with fever

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults, male or female aged 19 years or older
  • newly diagnosed with adrenal disease such as adrenal incidentaloma, pheochromocytoma, primary aldosteronism, adrenal cushing syndrome, adrenocortical carcinoma

Who cannot take part

  • previous or current history of adrenal diseases
  • using oral or intravenous steroids
  • history of major depressive disorder
  • history of chronic alcoholics
  • history of any cancer with suspicious adrenal metastasis
  • those with acute illness (ex- patients with acute coronary syndrome within 4 weeks, acute febrile disease)

Where in South Korea

  • Seoul National University HospitalSeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

The purpose of this study is to investigate the pathologic features, complications, and prognostic factors of functioning adrenal adenoma and suggest follow-up algorithms for adrenal incidentaloma.

The 5 groups in the trial

  • Non-functioning adrenal incidentaloma

    patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging

    Treatment: Hormone study and Imaging study

  • Pheochromocytoma

    patients who were diagnosed with pheochromocytoma biochemically or histologically

    Treatment: Hormone study and Imaging study

  • Primary aldosteronism

    patients who were diagnosed with primary aldosteronism by saline loading test

    Treatment: Hormone study and Imaging study

  • Adrenal cushing syndrome

    patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.

    Treatment: Hormone study and Imaging study

  • Adrenocortical carcinoma

    patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam

    Treatment: Hormone study and Imaging study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective Cohort Study for Patients With Adrenal Diseases
Plain-language title
Following people with adrenal gland diseases over timeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
18 March 2020